vildagliptin is another orally administered dipeptidyl peptidase-IV (DPP-IV) inhibitor following sitagliptin. It was approved for marketing in the European Union in 2008 by Novartis Pharmaceuticals GM…
Glimepirea is a long-acting antidiabetic drug of the third-generation sulfonylurea class. The main mechanism of its hypoglycemic effect is to stimulate pancreatic β cells to secrete insulin and partia…
Besagliflozin is an SGLT2 inhibitor. As a new type of hypoglycemic drug, SGLT2 inhibitors can increase the body's heat consumption, reduce fluid retention and increase the excretion of urine sugar by …
Canagliflozin is an SGLT2 inhibitor drug that can reduce blood sugar by breaking down glucose and excreting it through the kidneys. Besides good blood sugar control, The most remarkable feature of Can…
Miglitol, trade name Otiapin, is an α -glucosidase inhibitor with a pseudo-monosaccharide chemical structure. It inhibits more types of α -glucosidases than acarbose and voglitagbose. It does not caus…
dapagliflozin (ForxigaTM), a novel anti-diabetic drug jointly developed by Bristol-Myers Squibb and Astrazeneca, was approved for marketing by the European Medicines Agency (EMA) on November 12, 2012.…
Net (Empagliflozin), according to Mr Column by boehringer ingelheim and eli lilly company joint development of a type 2 sodium synergy of glucose transporters (SGLT - 2, sodium - dependentglucosecotra…
Repaglinide is a diabetes treatment drug, belonging to the non-sulfonylurea insulin-releasing agent class. It was successfully developed by the German company BoehringerIngelheim. In December 1997, it…
Saxagliptin is a type 2 diabetes treatment drug that can stimulate the pancreas to produce more insulin after meals. It was jointly developed by Astrazeneca of the United States and Bristol-Myers Squi…
Lipilidine is a DPP-IV inhibitor. Dpp-iv is an enteroinsulin-stimulating hormone that binds to proteins and exists in many tissues, such as the kidneys, liver, brush margins of the small intestinal me…
alogliptin benzoate, also known as alogliptin, is a serine protease dipeptidyl peptidase IV (DPP-IV) inhibitor developed by Takeda Corporation of Japan. This product can maintain the levels of glucago…
Sitagliptinphosphate (trade name Januvia, code MK-0431), commonly known as sitagliptin, is produced by Merck in the United States. It was approved for marketing by the US Food and Drug Administration …
Insulin glargine is an insulin analogue. On the double chain of insulin, one glycine is replaced respectively and two arginines are added. Therefore, it is called insulin glargine. The addition of the…
Insulin glulisine (HMR 1964) is a fast-acting insulin analogue that mimics the pharmacokinetic and pharmacodynamic characteristics of human physiological insulin. Insulin glulisine can be used in the …
Diabetes is a global chronic metabolic disease that requires lifelong treatment. Under the influence of genetic or environmental factors, pancreatic islet B cells are unable to secrete insulin or secr…
ECROBOT CO., Ltd, Business Registration Number : 220-88-71747, CEO J.W.Park, TEL : +82-2-552-7676, E-mail : E-mail : Contact us Address : (Hwanghwa B/D 11F, Yeoksam-dong)320, Gangnam-daero, Gangnam-gu, Seoul, South Korea